From Tomas Philipson; Forbes ~ Oct 06, 2016
The drug industry often claims that high prices are due to its high R&D costs, while industry critics argue that lower prices will not cut R&D. The evidence is clear that both sides are wrong and these arguments should be eliminated from the policy debate. Prices drive R&D spending, not vice versa.

